10月8日晚间,百济神州发布公告,披露旗下核心BTK抑制剂泽布替尼(商品名“百悦泽”)在美国市场被诉专利侵权的最新进展:百济神州及艾伯维旗下公司Pharmacyclics公司已向法院提交一份共同协议,自愿撤回案件,案件已做出终局处理。这意味着,这场历时两年多的跨国专利侵权诉讼案,百济神州获胜。 泽布替尼被诉专利侵权,百济神州获胜 泽布替尼是百济神州旗下最畅销的BTK抑制剂,2023年首次成为“...
Source Link10月8日晚间,百济神州发布公告,披露旗下核心BTK抑制剂泽布替尼(商品名“百悦泽”)在美国市场被诉专利侵权的最新进展:百济神州及艾伯维旗下公司Pharmacyclics公司已向法院提交一份共同协议,自愿撤回案件,案件已做出终局处理。这意味着,这场历时两年多的跨国专利侵权诉讼案,百济神州获胜。 泽布替尼被诉专利侵权,百济神州获胜 泽布替尼是百济神州旗下最畅销的BTK抑制剂,2023年首次成为“...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.